Real‐World Data Approaches for Early Detection of Potential Safety and Effectiveness Signals for Generic Substitution: A Metoprolol Extended‐Release Case Study

National trends in prescription drug expenditures and projections for 2018

(2018) Glen T. Schumock et al.   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis

(2018) Joshua D Wallach et al.   BMJ-British Medical Journal

Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis

(2018) Joshua D Wallach et al.   BMJ-British Medical Journal

Evaluation of Switching Patterns in FDA’s Sentinel System: A New Tool to Assess Generic Drugs

(2018) Joshua J. Gagne et al.   DRUG SAFETY

Brand vs generic adverse event reporting patterns: An authorized generic-controlled evaluation of cardiovascular medications

(2017) Y. Alatawi et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

The FDA's sentinel initiative-A comprehensive approach to medical product surveillance

(2016) R Ball et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Improving Adherence to Therapy and Clinical Outcomes While Containing Costs: Opportunities From the Greater Use of Generic Medications: Best Practice Advice From the Clinical Guidelines Committee of the American College of Physicians

(2015) Niteesh K. Choudhry et al.   ANNALS OF INTERNAL MEDICINE

Perceptions of generic medication in the general population, doctors and pharmacists: a systematic review

(2015) Sarah Colgan et al.   BMJ Open

A Systematic Review of Physicians’ and Pharmacists’ Perspectives on Generic Drug Use: What are the Global Challenges?

(2015) Else-Lydia Toverud et al.   Applied Health Economics and Health Policy

A Comparison of Active Adverse Event Surveillance Systems Worldwide

(2014) Yu-Lin Huang et al.   DRUG SAFETY

The Weber Effect and the United States Food and Drug Administration’s Adverse Event Reporting System (FAERS): Analysis of Sixty-Two Drugs Approved from 2006 to 2010

(2014) Keith B. Hoffman et al.   DRUG SAFETY

Systems Approaches in Risk Assessment

(2013) L J Lesko et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Postmarketing Safety Surveillance

(2013) Preciosa M. Coloma et al.   DRUG SAFETY

Data Mining of the Public Version of the FDA Adverse Event Reporting System

(2013) Toshiyuki Sakaeda et al.   International Journal of Medical Sciences

Use of administrative medical databases in population-based research: Table 1

(2013) Natalie Gavrielov-Yusim et al.   JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH

Comparing Generic and Innovator Drugs: A Review of 12 Years of Bioequivalence Data from the United States Food and Drug Administration

(2009) Barbara M Davit et al.   ANNALS OF PHARMACOTHERAPY

Quantitative signal detection using spontaneous ADR reporting

(2009) A. Bate et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY